EVALUATING THE COST-EFFECTIVENESS OF DIFFERENT GROUPS OF HYPERTENSION THERAPY: A PHARMACOECONOMIC STUDY

EVALUATING THE COST-EFFECTIVENESS OF DIFFERENT GROUPS OF HYPERTENSION THERAPY: A PHARMACOECONOMIC STUDY Roobena Parveen A Vara Prasanna Rao M

Objective: The study objective is to evaluate among the different groups of antihypertensive for their cost-effectiveness and to provide information about the effective management of hypertensives both clinically and economically. Methods: This study involves 81 patients aged 18–80 years on antihypertensive treatment who were enrolled from December to May with daily dose calculation. It is performed to analyze cost-effectiveness in the management of clinical condition. Data collection form to be entered with age, sex, food habits, occupational status, clinical data, and drugs was used for treatment. Incremental cost-effectiveness ratio is calculated based on the incremental cost for “per mmHg” reduction and cost for “per patient” reaching target blood pressure (BP). Result: Angiotensin receptor blockers (ARBs) show a significant average reduction of systolic BP (SBP) and beta-blockers (BBs) show an average reduction of diastolic BP (DBP). Angiotensin-converting enzyme inhibitors (ACEIs) are cost effective in SBP and calcium channel blockers are cost effective in maintaining DBP. Conclusion: ARBs, BBs, and ACEIs show the effective management of hypertensives both clinically and economically.
12 28 2018 10.22159/ajpcr.2018.v11s4.31738 https://innovareacademics.in/journals/index.php/ajpcr/article/view/31738 https://innovareacademics.in/journals/index.php/ajpcr/article/viewFile/31738/16651 https://innovareacademics.in/journals/index.php/ajpcr/article/viewFile/31738/16651